Institut Català de la Salut
[Alcubierre N] Avantmedic Center, Lleida, Spain. [Granado-Casas M] Department of Nursing and Physiotherapy, Health Sciences Faculty, University of Lleida, Lleida, Spain. Institute of Biomedical Research in Lleida (IRBLleida), Lleida, Spain. Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain. DAP-Cat Group, Unitat de Suport a la Recerca Barcelona, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain. [Bogdanov P, Hernández C, Ramos H, Simó R] Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain. Grup de Recerca de Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Castelblanco E] DAP-Cat Group, Unitat de Suport a la Recerca Barcelona, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain. Endocrinology, Metabolism and Lipid Research Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA
Vall d'Hebron Barcelona Hospital Campus
2023-03-29T10:26:25Z
2023-03-29T10:26:25Z
2023-02-25
Caffeine intake; Tea consumption; Type 2 diabetes
Consumo de cafeína; Consumo de té; Diabetes tipo 2
Consum de cafeïna; Consum de te; Diabetis tipus 2
The aim of this study was to assess the potential benefits of caffeine intake in protecting against the development of diabetic retinopathy (DR) in subjects with type 2 diabetes (T2D). Furthermore, we tested the effect of topical administration of caffeine on the early stages of DR in an experimental model of DR. In the cross-sectional study, a total of 144 subjects with DR and 147 individuals without DR were assessed. DR was assessed by an experienced ophthalmologist. A validated food frequency questionnaire (FFQ) was administered. In the experimental model, a total of 20 mice were included. One drop (5 μL) of caffeine (5 mg/mL) (n = 10) or vehicle (5 μL PBS, pH 7.4) (n = 10) was randomly administered directly onto the superior corneal surface twice daily for two weeks in each eye. Glial activation and retinal vascular permeability were assessed using standard methods. In the cross-sectional study in humans, the adjusted-multivariable model showed that a moderate and high (Q2 and Q4) caffeine intake had a protective effect of DR (odds ratio (95% confidence interval) = 0.35 (0.16–0.78); p = 0.011 and 0.35 (0.16–0.77); p = 0.010, respectively). In the experimental model, the administration of caffeine did not improve either reactive gliosis or retinal vascular permeability. Our results suggest a dose-dependent protective effect of caffeine in the development of DR, while the potential benefits of antioxidants in coffee and tea should also be considered. Further research is needed to establish the benefits and mechanisms of caffeinated beverages in the development of DR.
This research was funded by grant PS09/01035 from Instituto de Salud Carlos III. N.A. and M.G-C. held a predoctoral fellowship from ISCIII (FI11/0008) and Ministerio de Educación, Cultura y Deporte (FPU15/03005), respectively. CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM; the current study was led by group CB15/00071) and CIBER Epidemiología y Salud Pública (CIBERESP) are an initiative from the Instituto de Salud Carlos III (Plan Nacional de I + D + I and Fondo Europeo de Desarrollo Regional).
Article
Versió publicada
Anglès
Retinopatia diabètica - Factors de risc; Diabetis no-insulinodependent - Complicacions; Cafeïna; DISEASES::Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Angiopathies::Diabetic Retinopathy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors; DISEASES::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus, Type 2; CHEMICALS AND DRUGS::Heterocyclic Compounds::Alkaloids::Xanthines::Caffeine; ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus::complicaciones de la diabetes::angiopatías diabéticas::retinopatía diabética; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo; ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus::diabetes mellitus tipo II; COMPUESTOS QUÍMICOS Y DROGAS::compuestos heterocíclicos::alcaloides::xantinas::cafeína
MDPI
Nutrients;15(5)
https://doi.org/10.3390/nu15051169
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]